In this week’s video, Dr. Brian Durie points to ASCO 2017 presentations on new multiple myeloma drug combinations, monoclonal antibodies, and checkpoint inhibitors; however, he finds there are “no major breakthroughs” on myeloma from this year’s meeting.

BOTTOM LINE:
Even though ASCO 2017 offers no major breakthroughs, some fine-tuning discoveries can improve day-to-day care of myeloma patients.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
What exactly is high-risk myeloma and how should it be treated?
Next Post
ASCO 2017: Multiple Myeloma Overview -- Dr. Sagar Lonial

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.